Zhenyu Yue | Mount Sinai

Biography

Research Topics

Alzheimer's Disease, Apoptosis/Cell Death, Autophagy, Axonal Growth and Degeneration, Human Genetics and Genetic Disorders, Knockout Mice, Lysosomes/endosome, Molecular Biology, Neuro-degeneration/protection, Parkinson's Disease, Protein Degradation, Protein Kinases, Protein Trafficking & Sorting, Schizophrenia, Synapses

Multi-Disciplinary Training Area

Disease Mechanisms and Therapeutics (DMT), Neuroscience [NEU]

Publications

154

Publications

Selected Publications

Integrated proteomics reveals autophagy landscape and an autophagy receptor controlling PKA-RI complex homeostasis in neurons. Xiaoting Zhou, You Kyung Lee, Xianting Li, Henry Kim, Carlos Sanchez-Priego, Xian Han, Haiyan Tan, Suiping Zhou, Yingxue Fu, Kerry Purtell, Qian Wang, Gay R. Holstein, Beisha Tang, Junmin Peng, Nan Yang, Zhenyu Yue. Nature Communications

RAB12-LRRK2 complex suppresses primary ciliogenesis and regulates centrosome homeostasis in astrocytes. Xingjian Li, Hanwen Zhu, Bik Tzu Huang, Xianting Li, Heesoo Kim, Haiyan Tan, Yuanxi Zhang, Insup Choi, Junmin Peng, Pingyi Xu, Ji Sun, Zhenyu Yue. Nature Communications

Silencing Parkinson’s risk allele Rit2 sex-specifically compromises motor function and dopamine neuron viability. Patrick J. Kearney, Yuanxi Zhang, Marianna Liang, Yanglan Tan, Elizabeth Kahuno, Tucker L. Conklin, Rita R. Fagan, Rebecca G. Pavchinskiy, Scott A. Shaffer, Zhenyu Yue, Haley E. Melikian. npj Parkinson's Disease

View All Publications

Office Locations

Hess Center For Science & Med Floor 9 Room 9-106 (office); 9-201 Lab

1470 Madison Ave

New York, NY 10029

212 824 9144 to 9153 Lab

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Yue during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

Yunipeutics

Founder/Co-Founder/Partner

Yunipeutics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Yue during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

Yunipeutics

Founder/Co-Founder/Partner

Yunipeutics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.